Ninety percent of clinical drug development fails despite implementation of many successful
strategies, which raised the question whether certain aspects in target validation and drug …

Natural products and their structural analogues have historically made a major contribution
to pharmacotherapy, especially for cancer and infectious diseases. Nevertheless, natural …

G protein-coupled receptors (GPCRs) are the most intensively studied drug targets, mostly
due to their substantial involvement in human pathophysiology and their pharmacological …

CRISPR is becoming an indispensable tool in biological research. Once known as the
bacterial immune system against invading viruses, the programmable capacity of the Cas9 …

The diversity, modularity, and efficacy of CRISPR-Cas systems are driving a
biotechnological revolution. RNA-guided Cas enzymes have been adopted as tools to …

Proteins are the main targets of most drugs; however, system-wide methods to monitor
protein activity and function are still underused in drug discovery. Novel biochemical …

Radiotherapy is one of the most common countermeasures for treating a wide range of
tumors. However, the radioresistance of cancer cells is still a major limitation for …

Numerous drug treatments that have recently entered the clinic or clinical trials have their
genesis in zebrafish. Zebrafish are well established for their contribution to developmental …

Compact and versatile CRISPR-Cas systems will enable genome engineering applications
through high-efficiency delivery in a wide variety of contexts. Here, we create an efficient …

The CRISPR–Cas9 system has revolutionized gene editing both at single genes and in
multiplexed loss-of-function screens, thus enabling precise genome-scale identification of …